Login / Signup

SLE clinical trials: impact of missing data on estimating treatment effects.

Mimi Y KimJoan T MerrillCuiling WangShankar ViswanathanKen KalunianLeslie HanrahanPeter Izmirly
Published in: Lupus science & medicine (2019)
The potential advantages of applying MI to address missing data in an SLE trial include reduced bias when estimating treatment effects, and measures of precision that properly reflect uncertainty in the imputations. However, results can vary depending on the imputation model used, and the underlying assumptions should be plausible. Sensitivity analysis should be conducted to demonstrate robustness of results, especially when missing data proportions are high.
Keyphrases
  • clinical trial
  • electronic health record
  • systemic lupus erythematosus
  • big data
  • phase ii
  • rheumatoid arthritis
  • phase iii
  • study protocol
  • data analysis
  • risk assessment
  • human health
  • open label